Aurobindo, Heritage Accused Of Hiding Drug Contamination

By Nathan Hale (April 6, 2020, 9:20 PM EDT) -- Generic versions of Metformin produced by Aurobindo Pharma and Heritage Pharmaceuticals were contaminated with a possible carcinogen, according to a proposed Florida class action seeking to recover $124 million that health insurers paid for the popular diabetes drug.

MSP Recovery Claims Series LLC, a Medicaid and Medicare claims recovery specialist, filed the suit Friday in Miami federal court as an assignee of several health care benefit providers. MSP alleges that Aurobindo Pharma Ltd. and Heritage Pharmaceuticals Inc. both produced Metformin that contained dangerous levels of N-nitrosodimethylamine, or NDMA, which is thought to cause cancer and liver damage.

In its 41-page complaint,...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!